Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic.
The post Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial appeared first on MedCity News.
